Prompted by the beneficial impact of Plau–/– and Plaur–/– on the incident and severity of CIA, Almholt et al. (2018) used neutralizing murine monoclonal antibodies toward mouse uPA (mU1) or mouse uPAR (mR1) to treat progression of arthritis in the CIA model. This evidence concerns the gene PLAUR and arthritic joint disease.